Clinical Evidence: What the Trials Actually Show
Is Mounjaro Better Than Wegovy: Understanding the Mechanisms
The question of whether Mounjaro is better than Wegovy cannot be answered definitively without considering individual patient factors and clinical context. Mounjaro (tirzepatide) operates as a dual incretin receptor agonist, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Wegovy (semaglutide) functions as a selective GLP-1 receptor agonist, focusing exclusively on this single pathway. Both prescription-only medicines work by reducing appetite and promoting satiety, but their different receptor profiles may influence how patients respond to treatment.
The dual-action mechanism of Mounjaro theoretically provides additional metabolic benefits through GIP receptor activation, which may enhance insulin sensitivity and glucose metabolism. However, Wegovy's targeted GLP-1 approach has been extensively studied in the STEP clinical trial programme, providing robust evidence for its effectiveness in weight management. Both treatments require careful dose escalation and must be used alongside a reduced-calorie diet and increased physical activity. Your prescriber at EverydayMeds can evaluate which mechanism may be more appropriate based on your medical history and treatment goals.
Wegovy Weight Loss Results: STEP Trial Evidence
When evaluating whether Mounjaro is better than Wegovy, examining the clinical evidence from peer-reviewed studies is essential. The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 3 trial showed even higher results of approximately clinically studied weight loss when combined with intensive behavioural therapy.
Long-term sustainability data from STEP 5 revealed that patients maintained approximately clinically studied weight loss at two years, whilst the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events. These results represent average outcomes from controlled clinical trials and individual results may vary significantly. It's important to note that direct comparisons between Mounjaro and Wegovy trial data should be interpreted cautiously, as different study designs, populations, and endpoints make head-to-head comparisons potentially misleading.
UK Pricing Structure: Mounjaro vs Wegovy Cost Analysis
Cost considerations often influence whether patients perceive Mounjaro as better than Wegovy for their circumstances. At EverydayMeds, Wegovy pricing begins at £79.99 for the 0.25mg starter dose, with new customers applying discount code FIRST40 at checkout to reach this price point. The complete dose escalation follows a structured progression: 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Our bundle options provide convenience for patients requiring continuous supply, such as the Intro Trio (0.25mg, 0.5mg, and 1mg) for £299.99.
Mounjaro pricing varies significantly from Wegovy, and availability through UK prescribing channels may differ. Both treatments represent substantial monthly investments, making the choice between them partly dependent on individual financial circumstances and insurance coverage. EverydayMeds provides transparent pricing without hidden fees, and returning customers can use discount code DOSE25 for ongoing treatment. The total cost of either treatment should be weighed against the potential long-term health benefits and the expense of alternative weight management approaches.
How Wegovy Works: GLP-1 Receptor Mechanism
Understanding how Wegovy functions helps patients determine whether Mounjaro might be better than Wegovy for their specific needs. Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone produced in the intestines after eating. This hormone normally signals the brain's appetite centres to reduce hunger and increase feelings of fullness after meals. By activating GLP-1 receptors, Wegovy may help patients feel satisfied with smaller portions and experience reduced food cravings. The medication also slows gastric emptying, which contributes to prolonged satiety between meals. This targeted mechanism has been refined through years of clinical development and represents a well-understood approach to weight management support.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing either treatment through our regulated UK pharmacy involves a streamlined but thorough process designed to ensure patient safety and treatment suitability. The initial step requires completing a comprehensive 3-minute online clinical assessment covering medical history, current medications, weight management goals, and contraindications. Our qualified prescribers, operating under GPhC registration #9012878, review each assessment within three working days (or 24 hours with express service). Once approved, prescriptions are fulfilled through our temperature-controlled cold-chain delivery system, ensuring medication integrity during transit. Next-day delivery is standard for approved prescriptions, with discrete packaging maintaining patient confidentiality. This regulated approach ensures both treatments meet MHRA standards and provide patients with genuine, properly stored medications.
Storage and Practical Considerations: Wegovy vs Mounjaro Logistics
Practical factors may influence whether patients find Mounjaro better than Wegovy for their lifestyle requirements. Wegovy offers superior storage flexibility, remaining stable at room temperature (below 30°C) for up to six weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for patients who travel frequently or lack consistent refrigerator access. Both medications use pre-filled pen devices, but Wegovy's FlexTouch pen system has been refined through Novo Nordisk's extensive diabetes treatment experience. The weekly injection schedule applies to both treatments, though dose escalation timelines differ slightly. Storage requirements mandate refrigeration at 2-8°C before first use, making both treatments unsuitable for patients unable to maintain proper storage conditions.
Determining Whether Mounjaro Is Better Than Wegovy: Individual Factors
The superiority of either treatment depends entirely on individual patient characteristics, medical history, and treatment response rather than universal effectiveness rankings. Patients with predominantly appetite-driven eating patterns may respond well to either GLP-1-based approach, while those with complex metabolic factors might theoretically benefit from Mounjaro's dual-receptor mechanism. However, clinical decision-making should always prioritise evidence-based medicine over theoretical mechanisms. Previous experience with incretin-based treatments, family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and concurrent medications all influence treatment selection.
Geographic availability and prescriber familiarity also affect treatment choice, as not all UK clinicians have equal experience with both options. EverydayMeds provides access to experienced prescribers familiar with both treatments, enabling evidence-based selection rather than availability-driven choices. Both Wegovy and Mounjaro are available through our regulated pharmacy service, allowing your prescriber to help determine which option aligns best with your clinical profile and treatment objectives.
Making Your Decision: Expert Support and Next Steps
Rather than determining whether Mounjaro is definitively better than Wegovy, focus on identifying which treatment offers the most appropriate risk-benefit profile for your circumstances. EverydayMeds simplifies this decision through expert prescriber consultations, transparent pricing, and reliable UK supply chains for both medications. New customers can begin their assessment using discount code FIRST40, while returning patients apply code DOSE25 for continued treatment. Our clinical team combines extensive experience with both treatments alongside personalised assessment of your medical history and weight management goals. Start your consultation today at https://everydaymeds.co.uk/collections/wegovy to explore which evidence-based treatment option may be most suitable for your needs. Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
